Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

250.43

+1.61 (0.65%)

as of Jul 21, 2026, 4:40:36 pm Market Open.

697 watching

Investor Insights

Jul 21, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

Johnson & Johnson (JNJ) has shown strong performance in the pharmaceutical sector, particularly after spinning off its orthopedics division. Despite challenges in the cardio business and ongoing talcum-cancer lawsuits, expert opinions are largely optimistic about the company's future prospects. The current focus on high-margin areas like medical devices and pharmaceuticals, combined with a strong drug pipeline, positions JNJ for growth. Although the stock may experience fluctuations around earnings reports, it is generally viewed as a buy during dips. Overall, experts suggest that JNJ remains a sound investment, particularly for those interested in dividend growth and potential additional upside.

Consensus

Buy

Valuation

Fair Value

Similar

DON'T BUY

Over time, the model price has been coming down. He has a model price of $60.18, a -14% differential.

TOP PICK

Medical devices and pharmaceuticals have been doing very well. Has a global franchise and growing very nicely outside of North America. Positive earnings revisions.

BUY

Likes their non-prescription healthcare products business. Good P/E multiple and good dividend.

BUY

If you like pharmaceuticals, consider moving into Johnson & Johnson (JNJ-N).

HOLD

Only partly a big pharmaceutical. Also into medical devices, consumer products, cosmetic products so it is more diversified.

BUY

(Market Call Minute.) Have been held back by the pharmaceutical side of the business but the medical devices and consumer products is good.

COMMENT

Has done a great job in anybody's portfolio. Very stable price while the market has gyrated. Has performed so well on a relative basis that there may not be a lot left.

PAST TOP PICK

(A Top Pick May 8/07. Up 7%.) Now that the Cdn$ is below par, he is comfortable with the US market. Nice dividend yield and a low PE.

Wealthica Track your Stocks in your Watch List

BUY ON WEAKNESS

Has the medical side as well as the consumer side. Its medical device side is facing a bit of problem and its drugs are likely to face increased scrutiny if there is a Democratic administration. Attractive in the $55-$58 range.

BUY

Wonderful company. Great management. Very strong balance sheet. Gives a bit of exposure in the Pharma and medical supply businesses as well as the consumer business. A good core holding. 2.65% yield.

DON'T BUY

In the near term, he would avoid this one. Expensive compared to other pharmaceutical companies. Has some major drugs coming off patents. Some big question marks regarding its stent business. If it comes off some more, it's a good long-term stock to own.

DON'T BUY

One of the better performing drug related stocks. Part pharmaceutical, part medical devices and part consumer products. Consumer product area has done well. Stent has not been doing well. Where doing well on the drug side but have a number of drugs coming off patent in the next few years. Expensive at 15-16X 2009 earnings for a company whose growth rate is slowing down. (See his top picks for a drug stock.)

BUY

Very high-quality company. There are some issues around their stent business, but long-term it doesn't get much better. Trades at historically low multiple of about 15X.

BUY

Owning this gives him the buffer between the non-patent products/devices to the pharmaceuticals. Very inexpensive.

BUY

A very sound financial company, growing its earnings at 8% to 10% per year. Trades at about 15X earnings. 2.5% dividend yield. Pristine AAA balance sheet. A very stable holding.

Showing 511 to 525 of 628 entries

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

David Driscoll

Liberty International Investment Management Inc

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Capital Area Planning Group

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Johnson & Johnson (JNJ)